Medical Condition News

RSS

ACOEM awareness campaign helps employers identify and respond to chronic diseases

The American College of Occupational and Environmental Medicine (ACOEM) today announced a yearlong awareness-building campaign intended to help employers identify and respond to chronic diseases that commonly impact worker health and productivity.

6 Sep 2012

Patients at hospitals with longer resuscitation attempts have higher survival rates

There isn't a hard and fast rule for how long doctors should perform CPR, but new research from the University of Michigan Health System shows longer attempts might be beneficial for some patients.

6 Sep 2012

Biologic therapies do not increase risk of cancer in patients with rheumatoid arthritis

Biologic therapies developed in the last decade for rheumatoid arthritis are not associated with an increased risk of cancer when compared with traditional treatments for the condition, according to new research from The University of Texas MD Anderson Cancer Center.

6 Sep 2012

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

Pfizer Inc. announced today the U.S. Food and Drug Administration (FDA) has approved BOSULIF (bosutinib), an Abl and Src kinase inhibitor, for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.

6 Sep 2012

Study sheds new light on why most bone marrow transplant patients suffer acute GVHD

A team of scientists led by a bone marrow transplant researcher at Fred Hutchinson Cancer Research Center has shed new light on why most bone marrow transplant patients who receive tissue-matched cells from unrelated donors still suffer acute graft-versus-host disease (GVHD).

6 Sep 2012

Endovascular repair for abdominal aortic aneurysms has low rate of complications

A minimally invasive procedure known as endovascular repair used for abdominal aortic aneurysms has a low rate of complications, even in high-risk patients such as those with kidney, heart or lung problems, a Mayo Clinic study shows.

6 Sep 2012

ImmunoCellular completes enrollment in ICT-107 Phase II trial for glioblastoma

ImmunoCellular Therapeutics, Ltd. announced today that the company has completed enrollment for its Phase II randomized, double-blinded, placebo-controlled, multi-center trial of its dendritic cell-based cancer vaccine ICT-107 for treatment of glioblastoma.

6 Sep 2012

TSC and PTEN genes important in controlling blood precursor cells in Drosophila

UCLA stem cell scientists have shown that two common tumor suppressor genes, TSC and PTEN, are vital to regulating the stem cell-like precursor cells that create the blood supply in Drosophila, the common fruit fly.

6 Sep 2012

DuraSite 2 ophthalmic drug delivery system from InSite Vision

InSite Vision Incorporated today introduced DuraSite 2, its next-generation enhanced drug delivery system which provides a broad platform for developing superior ophthalmic therapeutics.

6 Sep 2012

LIN28 protein can bind directly to thousands of messenger RNAs

A study led by researchers at the UC San Diego Stem Cell Research program and funded by the California Institute for Regenerative Medicine (CIRM) looks at an important RNA binding protein called LIN28, which is implicated in pluripotency and reprogramming as well as in cancer and other diseases.

6 Sep 2012

Two UNC autism researchers receive $12.6 million in grants from ACE program

Two autism researchers in the University of North Carolina School of Medicine have each been awarded $12.6 million grants in the latest round of funding from the National Institutes of Health's Autism Centers of Excellence (ACE) research program.

6 Sep 2012

Rigel commences R343 and R333 Phase 2 studies in allergic asthma, discoid lupus erythematosus

Rigel Pharmaceuticals, Inc. today announced that it has commenced Phase 2 clinical studies with two of the company's most advanced proprietary therapeutic product candidates. R343 is an inhaled SYK inhibitor that is being evaluated as a potential treatment for allergic asthma.

6 Sep 2012

Kinetic Concepts launches Skin IQ 1000 MCM to help prevent and treat stage I-IV pressure ulcers

Kinetic Concepts, Inc. (KCI) announced today the U.S. launch of the Skin IQ 1000 Microclimate Manager (MCM) by its Therapeutic Support Systems (TSS) business.

6 Sep 2012

Roundup: Cancer drug cost equity bill sitting on Calif. Gov's desk; Mass. cost-containment law could harm provider credit ratings

Out-of-pocket costs for cancer drugs can vary dramatically depending on whether the medications are administered through pill form or intravenous infusion. Newer oral drugs, which can be taken at home and often have fewer side effects than older drugs, can cost patients thousands of dollars a month, while receiving chemotherapy through an IV in an infusion center typically amounts to a standard co-payment for an office visit.

6 Sep 2012

Complex spine minimally invasive retractor system launched by K2M

K2M, Inc., the largest privately held spinal device company in the world focused on developing innovative solutions for the treatment of complex spinal pathologies and minimally invasive procedures, today announced the launch of the SERENGETI® Complex Spine Minimally Invasive Retractor System at the Scoliosis Research Society (SRS) 47th Annual Meeting in Chicago.

5 Sep 2012

People with generalized anxiety disorder have weak brain connections

A new University of Wisconsin-Madison imaging study shows the brains of people with generalized anxiety disorder (GAD) have weaker connections between a brain structure that controls emotional response and the amygdala, which suggests the brain's "panic button" may stay on due to lack of regulation.

5 Sep 2012

Study questions use of vitamin D supplements to improve cholesterol

Vitamin D has been touted for its beneficial effects on a range of human systems, from enhancing bone health to reducing the risk of developing certain cancers. But it does not improve cholesterol levels, according to a new study conducted at The Rockefeller University Hospital.

From Quest Diagnostics 5 Sep 2012

NeuroSigma's external Trigeminal Nerve Stimulation system awarded CE Certification

NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that it received CE Certification for its external Trigeminal Nerve Stimulation (eTNS) system, called the Monarch, for the adjunctive treatment of epilepsy and major depressive disorder, for adults and children 9 years and older.

5 Sep 2012

Enrollment complete in ACADIA's pimavanserin Phase III trial for Parkinson's disease psychosis

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the completion of enrollment in its ongoing pivotal Phase III trial with pimavanserin in patients with Parkinson's disease psychosis (PDP).

5 Sep 2012

Epizyme commences EPZ-5676 Phase 1 study for MLL-r leukemia

Epizyme, Inc., a company leading the creation of a new class of personalized therapeutics for patients with genetically defined cancers, announced today that it has initiated a Phase 1 Study of EPZ-5676. EPZ-5676 is a novel small molecule inhibitor of DOT1L, a histone methyltransferase (HMT) that is critical to the development of a specific type of acute leukemia defined by rearrangement of the MLL gene (MLL-r leukemia).

5 Sep 2012

Medical Condition News

ACOEM awareness campaign helps employers identify and respond to chronic diseases

Patients at hospitals with longer resuscitation attempts have higher survival rates

Biologic therapies do not increase risk of cancer in patients with rheumatoid arthritis

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

Study sheds new light on why most bone marrow transplant patients suffer acute GVHD

Endovascular repair for abdominal aortic aneurysms has low rate of complications

ImmunoCellular completes enrollment in ICT-107 Phase II trial for glioblastoma

TSC and PTEN genes important in controlling blood precursor cells in Drosophila

DuraSite 2 ophthalmic drug delivery system from InSite Vision

LIN28 protein can bind directly to thousands of messenger RNAs

Two UNC autism researchers receive $12.6 million in grants from ACE program

Rigel commences R343 and R333 Phase 2 studies in allergic asthma, discoid lupus erythematosus

Kinetic Concepts launches Skin IQ 1000 MCM to help prevent and treat stage I-IV pressure ulcers

Roundup: Cancer drug cost equity bill sitting on Calif. Gov's desk; Mass. cost-containment law could harm provider credit ratings

Complex spine minimally invasive retractor system launched by K2M

People with generalized anxiety disorder have weak brain connections

Study questions use of vitamin D supplements to improve cholesterol

NeuroSigma's external Trigeminal Nerve Stimulation system awarded CE Certification

Enrollment complete in ACADIA's pimavanserin Phase III trial for Parkinson's disease psychosis

Epizyme commences EPZ-5676 Phase 1 study for MLL-r leukemia

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News